October 10, 2012

Higher-dose Exelon Patch approved for Alzheimer's

Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Similar Articles

More in Products

HealthLease purchase completed

CFG Capital Markets, the investment banking platform of Capital Funding Group, announced it was an advisor on a $141.7 million portfolio.

Bulk TV & Internet announce partnership

Bulk TV & Internet has become an authorized partner of Mitel, a provider of cloud and premises-based unified communications and collaboration software.

Oak Grove Capital closes line for Brookdale

Oak Grove Capital announced it has closed a $259 Fannie Mae DUS credit facility for Brookdale Senior Living.